Home - nova-sessions

Cannabidiol (CBD) – potential billion dollar market, but still barriers in the legal framework

Be up to date – don’t miss your investment opportunity, but also be aware of the barriers

nova Session “CBD (cannabidiol) as a food additive, body care and pharmaceutical – effects, production, authorisation and legislation”

17 September 2019, 10:00-16:30 h

Wöllhaf Conference Center
Terminal 1, Airport Cologne/Bonn, Germany

CBD is becoming a new billion-dollar market worldwide. In the nova session you will learn everything about CBD: how it has a pharmacological effect, how it is produced, what applications it has and, above all, what the legal regulations look like in which countries. While new markets are already emerging in North America and Israel, Europe is still struggling to regulate CBD so that safe and legal products find their customers.

Leading experts from Great Britain, Germany, Italy and Brussels, all members of the European Industrial Hemp Association, will bring you up to date and discuss with you extensively. Join in, learn, discuss and share.

Michael Carus, nova-Institut (DE)

Introduction and moderation
Latest scientific findings
CBD in medical applications

Daniel Kruse, Managing Director of HempConsult and EIHA board member (DE)

EIHA consortium for Novel Food application
Concept & background
Timeline & costs

Joscha Krauss, MH MedicalHemp (DE)

Hemp varieties
Cultivation, harvesting and drying
Extraction of CBD
Applications in cosmetics and food supplements

Lorenza Romanese, Managing Director of EIHA (IT/BE)

Hemp Extracts are not Novel
Sharing all EIHA evidences on Hemp Extracts
EIHA position and actions

Catherine Wilson, CannaWellness and EIHA board member (UK)

History of Novel Food catalogue, changes in classification of Cannabis Sativa / CBD over the years and current status
EU labelling requirements & health claims regulations